Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Up 27.7% in December

Aileron Therapeutics, Inc. (NASDAQ:ALRN) was the recipient of a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 141,200 shares, an increase of 27.7% from the December 15th total of 110,600 shares. Currently, 0.7% of the company’s stock are short sold. Based on an average daily volume of 95,500 shares, the short-interest ratio is currently 1.5 days.

Institutional Investors Weigh In On Aileron Therapeutics

Large investors have recently modified their holdings of the stock. KG&L Capital Management LLC acquired a new position in Aileron Therapeutics during the 3rd quarter worth approximately $46,000. Sigma Planning Corp raised its stake in shares of Aileron Therapeutics by 68.3% during the third quarter. Sigma Planning Corp now owns 212,410 shares of the company’s stock valued at $752,000 after purchasing an additional 86,185 shares during the period. Geode Capital Management LLC lifted its position in shares of Aileron Therapeutics by 34.8% during the third quarter. Geode Capital Management LLC now owns 229,817 shares of the company’s stock worth $814,000 after purchasing an additional 59,370 shares in the last quarter. Nantahala Capital Management LLC boosted its stake in shares of Aileron Therapeutics by 82.1% in the second quarter. Nantahala Capital Management LLC now owns 464,367 shares of the company’s stock valued at $1,286,000 after purchasing an additional 209,367 shares during the period. Finally, University of Texas Texas AM Investment Management Co. acquired a new stake in Aileron Therapeutics during the 2nd quarter valued at $4,925,000. Institutional investors and hedge funds own 90.89% of the company’s stock.

Aileron Therapeutics Stock Performance

The firm has a 50 day moving average of $2.52 and a 200-day moving average of $2.80. Aileron Therapeutics has a 52-week low of $1.61 and a 52-week high of $7.42.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).